Markets Wrap – Wed, 22 Feb ‘23- Nifty, Sensex crash, rupee falls; Asia, US markets, Gold, Crude updates
时间:2024-06-26 12:56:36 阅读(143)
Domestic indices suffered huge losses on Wednesday dragging Nifty 50 below 17,560 and Sensex below 59,750. Bank Nifty breached the crucial level and closed below 40,000 as the negative global market sentiments triggered bloodbath on Dalal street. The only gainers on the Nifty 50 were ITC (up 0.50%) and Bajaj Auto (up 0.26%) while Adani Enterprises (down 11.05%), Adani Ports (down 7.24%), Grasim (down 3.44%), Bajaj Finance (down 2.94%) and JSW Steel (down 2.79%) were the losers.US Markets
The US markets ended Tuesday’s session broadly lower with Dow Jones Industrial Average tanking 697.01 pts or 2.06% to 33,129.59, tech-heavy Nasdaq sank 294.97 pts or 2.50% to 11,492.30 and S&P 500 plunged 81.75 pts or 2% to 3,997.34.
Asian MarketsAsian markets closed in the red territory on Wednesday. China’s Shanghai Composite Index fell 0.47%, South Korea’s KOSPI tanked 1.68%, Japan’s Nikkei 225 was down 1.34%, and Hong Kong’s Hang Seng tumbled 0.51%.
Rupee movementThe Indian rupee fell marginally by 0.05% to 82.85 against the US dollar at 3:52 PM (IST).
Gold, SilverGold futures on the multi-commodity exchange for April delivery were trading at Rs 56,140.00, down 28 points or 0.05% while Silver futures for March delivery fell 305 points or 0.46% to Rs 65,747.00.
Crude oilWTI Crude futures for March delivery were down 1.75% at $75.02 while Brent Crude futures for March delivery were trading 1.43% lower at $81.86 at 3:55 PM (IST).
The Japanese pharma major is also filing a plea before the Delhi HC seeking appointment of forensic auditors to analyse transactions involving IHH, Fortis Healthcare and RHT, Singapore, as directed by the HC on October 18.
The development is likely to create legal hurdles and delay the proposed open offer as IHH had recently told FE that it could only go ahead if Sebi agreed with its legal interpretation that the SC’s September 22 order has lifted all such restraints.
IHH managing director and CEO Kelvin Loh told FE on November 9 that the company would like to go ahead with the open offer “as soon as possible” as there has already been a delay of four years. Ravi Rajagopal, chairman of Fortis Healthcare, had added that their legal counsel has advised that the company can go ahead with the open offer as the SC order has disposed of various appeals, including the suo motu contempt. “We have represented to the Sebi and the matter is with them,” Rajagopal had said.
However, legal observers told FE that the matter is not that straightforward and simple as the Delhi HC has to take the final call on the matter of open offer as well as whether a forensic audit has to be done in the share sale which was executed in 2018.
Also Read: IHH to float open offer for Fortis if Sebi concurs with our legal view: MD & CEO
Loh and Rajagopal had said the possibility that the matter may take a different turn when it comes up in Delhi HC cannot be ruled out.
IHH had in July 2018 acquired a 31% stake in Fortis Healthcare for Rs 4,000 crore through the bidding route. It had also earmarked Rs 3,000 crore to make an open offer for an additional 26% to the public shareholders as required under the law.
Daiichi has written to Sebi that the SC in its September 22 order had asked the HC to consider ordering a forensic audit into the dilution of FHL shareholding, repeated violation of undertakings and assurance by former FHL promoters — Malvinder and Shivinder Singh — and the transaction between FHL, IHH and the clandestine transfer of Rs 4,666 crore to RHT Singapore.
Daiichi is “severely prejudiced” with IHH’s clandestine attempt to subvert the status quo order directed by the SC on December 14, 2018, and September 22 with respect to the conduct of forensic audit and the pending proceedings before the HC by purportedly consulting regulatory authorities, including Sebi, on the proposed FHL-IHH transaction. It has reiterated that the FHL-IHH transaction was currently sub-judice before the HC where FHL is also a party, its solicitors, P&A Law Offices, have said in the letter.
“We further state that any such attempt by FHL and/or IHH to proceed with the FHH-IHH transaction would be in direct contravention of the HC and SC orders,” the letter sent by the law firm has stated. Daiichi Sankyo is pursuing the enforcement of Rs 3,500-crore arbitration award against the Singh brothers pronounced by a Singapore tribunal for concealing information when they sold Ranbaxy Laboratories to it for $4.6 billion in 2008. The apex court had in 2018 put on hold the sale of Fortis Healthcare to IHH on a contempt plea filed by the Japanese drugmaker against the Singh brothers.
猜你喜欢
- In Pictures - From New York to Bangkok, the world unites to welcome the new year 2024
- Jyoti CNC Automation sets IPO price band at Rs 315-331 per share
- Kotak Mahindra Bank share price jumps 5
- Maruti Suzuki India’s 2nd cohort of mobility start-up competition sees Woloo, Hala Mobility and SwitchOn win big
- Mehta Equities’ stocks recommendation for the week_2
- KEI Industries stock jumps 3% today after falling 6% on Tuesday; should you buy, sell, hold KEI shares-
- MCX gold trend likely to remain higher, but traders must wait for dip around 51500-51200 for fresh trade
- Markets Wrap – Wed, 11 Jan ‘23- Stocks fall, rupee gains; Asia, Europe markets, Gold, Crude, Crypto updates
- Meet Thailand’s King Maha Vajiralongkorn- Owner of 38 aircraft, 300 cars, and a Rs 98 crore diamond; though not surpassing Mukesh Ambani or Gautam Adani in wealth